GST No. : 09AAMCM4977D1Z0
Udyam No. : UDYAM-UP-29-0013929
  : +91 7428578883  : info@scienxt.com
Journal Particulars
Title Scienxt International Journal of Drug Development
Frequency Biannual (June, December)
Publisher Scienxt Center of Excellence(P) Ltd
Chief Editor Dr. Shaik Aminabee
Copyright @Scienxt Center of Excellence(P) Ltd
Subject  Drug Development
Language English
Publication Format Print + Online
Phone No 7428578883
Email Id info@scienxt.com
Website https://scienxt.com/sijdd/
Address Scienxt Center of Excellence(P) Ltd, Plot No-4, Institutional Area, Sector-16A, Noida, Uttar Pradesh -201301
Indexing Google Scholar, Zenodo, Figshare, Academia, Scribd, ResearchGate

SIJDDDS – Scienxt International Journal of Drug Delivery and Drug Safety, Double blind peer-reviewed Journal, disseminates the most recent findings and innovations in various fields of Drug Delivery and Drug Safety in the form of Original Research, Reviews, Case Studies, Opinions, etc. Journal maintains a Quick Publication process with strict peer review to enhance the quality of content. Every submitted manuscript undergoes peer review by the subject matter experts under the supervision of the Editor-in-Chief or assigned Editorial Board member of the Journal.

The Journal also publishes conference proceedings.

Scope & Focus

SIJDDDS Journal has the following scope and focus but, not limited to these: Antibodies, Cell and Gene Therapy, RNA-Based Therapeutics and mRNA Vaccines, CRISPR and Genome Editing for Drug Development, Biomarker Discovery and Companion Diagnostics, Targeted Drug Delivery and Smart Nanocarriers, Drug Repurposing and Repositioning, Biopharmaceutical Manufacturing and Quality Control, Advanced Drug Screening Models – Organoids and 3D Cell Cultures, Microfluidics and Lab-on-a-Chip Technologies,Drug Discovery and Target Identification, High-Throughput Screening and Lead Optimization, Structure-Based Drug Design, Pharmacokinetics and Pharmacodynamics (PK/PD), Preclinical Drug Development, Toxicology and Safety Assessment, Clinical Trials – Phase I, II, III, and IV, Regulatory Affairs and FDA/EMA Compliance, Biologics and Biosimilars Development, Nanotechnology in Drug Development.

You can submit your manuscript(s) online at info@scienxt.com

  Current Issue

  Archive

Wordpress Social Share Plugin powered by Ultimatelysocial